Prostate Cancer Clinical Trial

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Summary

Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be enrolled. Additional subjects may be enrolled if there is insufficient data for evaluation, for example if the original study subjects do not complete required imaging studies for reasons unrelated to adverse events.

Up to four PSMA-Targeted [In-111]-Labeled Trillium Compounds will be evaluated. Each compound will be evaluated first without the cytoprotective agent, PTI-122, then the [In-111]-labeled Trillium Compound may be co-administered with PTI-122.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult males with metastatic prostate cancer
ECOG performance score 0-2
Stable androgen deprivation or other hormone therapy (30 days) or therapy planned but not yet initiated

PSMA PET scan between 3 and 28 days prior to radiotracer injection with at least 2 PSMA positive lesions and either:

One soft tissue lesion measuring ≥ 15 mm in the longest diameter with SUVmax lesion ≥ SUVmean normal liver, OR
Two bone lesions measuring ≥ 15 mm in the longest diameter with SUVmax lesion ≥ 2 x SUVmax normal liver
Able to understand and adhere to study requirements, and voluntarily give informed consent

Exclusion Criteria:

No other malignancy undergoing treatment
No PSMA-targeted therapy ongoing
Inability or unwillingness to undergo SPECT/CT imaging
Serum creatinine > 1.5 mg/dL or creatinine clearance ≤50 mL/min by Cockcroft-Gault estimation
Concurrent participation in the active treatment phase of another clinical trial of investigational medicinal product(s)
Significant intercurrent illness, treatment-related toxicity, or psychiatric illness/social situation that could place the subject at undue risk during study participation, significantly alter study outcomes, or affect subject compliance with study requirements for dosing and evaluation, as determined by the investigator

Study is for people with:

Prostate Cancer

Phase:

Early Phase 1

Estimated Enrollment:

23

Study ID:

NCT05773703

Recruitment Status:

Completed

Sponsor:

Ratio Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Biogenix Molecular
Miami Florida, 33165, United States
Advanced Molecular Imaging & Therapy
Glen Burnie Maryland, 21061, United States
XCancer Omaha/Urology Cancer Center
Omaha Nebraska, 68130, United States
University of Tennessee Medical Center
Knoxville Tennessee, 37920, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Early Phase 1

Estimated Enrollment:

23

Study ID:

NCT05773703

Recruitment Status:

Completed

Sponsor:


Ratio Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.